Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The cost and control manager is probably just to keep track of all the Leronlimab doctors will be ordering for the OLE and new eIND's. Next month they will need an entire department.
Leronlimab was just approved for open label extension in the CD12 covid trial, this was after the FDA had access to the data. The FDA would not have approved a drug that was not working, so the writing is on the wall, Leronlimab is working and will be approved in a matter of days.
https://www.cytodyn.com/investors/news-events/press-releases/detail/495/fda-accepts-protocol-for-adding-an-open-label-extension-to
Here's the trial that was just given partial approval
https://clinicaltrials.gov/ct2/show/NCT04347239
Wondering if the partial approval of Leronlimab in CD12 is enough for OWS to begin manufacturing or will they wait untill the FDA goes through the motions of full approval.
So with having access to CD12 data the FDA green lights Leronlimab for ALL patients? The writings on the wall it spells approval!!
He's in San Francisco, running CytoDyn's cancer basket trial. The trial that's showing very good results, the trial that CytoDyn will be discussing on January the 6th.
Very nice!!!
It could come alot sooner than they expect. I can see a midday PR announcing clearance for the OLE.
WOW, did you say the owner of the Rockies was an early investor in CYDY?
Let's do a quick recap on what brought Leronlimab to a phase 2B/3 trial. The FDA looked at data presented by CytoDyn from eIND patients being treated for severe to critical covid-19. They were impressed enough seeing the results they granted the phase 3 trial bypassing the standard phase 1 and 2. Leronlimab hasn't changed it's going to show the same incredible results from the trial as it did the eIND patients and in a matter of days the whole world will see it. Don't blink
CYDY gap open to $5.95 close at $7 on Monday. Seeing the strength CYDY had last week just on fomo alone this solid news will bring in a flood of new investors, that combined with the panicked shorts and day traders trying to buy back in it's going to be an exciting week for CYDY longs. We get to sit back and enjoy the show!
Zacks upgraded CYDY to hold
https://www.marketbeat.com/instant-alerts/otcmkts-cydy-a-buy-or-sell-right-now-2020-12/
This price increase looks like way more than the pop from CD12 enrollment. This looks more like people in the know buying. Something approved over seas? Nasdaq uplist? OWS? Whatever it is this is just the beginning, headed to $10 then $30, $50, $100
CYDY is on its way to $10 before approval. And with two PR's due out next week it could get there by Christmas with help from our short friends squeezing each other into bankruptcy. It's a good time to be a CytoDyn investor. Don't blink!
NP quote, "CytoDyn is a loving company not a hateful one" prayers for your wife Marksch1, wishing her a speedy recovery and good days for you both.
So... you're posting a graph...that shows medicare issued a billing code to LERONLIMAB.... specifically says LERONLIMAB...Why does medicare need a billing code for LERONLIMAB?
WRONG AGAIN here it states only 4 Mab's , and goes on to mention specifically Leronlimab is the only Mab that doesn't need an IV
DEBUNKED AGAIN...STILL LAUGHING
https://yes-himconsulting.com/27-new-icd-10-codes-for-covid-19-related-conditions-monoclonal-antibodies-more-take-effect-january-1-2021/
They are definitely sweating it. With more PR's due out at anytime CYDY is a ticking time bomb for shorts.
WRONG only 6 drugs were assigned codes. Leronlimab is the first one listed
DEBUNKED... LAUGHING
https://www.icd10monitor.com/cms-releases-new-icd-10-pcs-codes-for-covid-19
Medicare and medicaid have expressed interest in CytoDyn. Assigning a billing code for Leronlimab. The only possible way to bill is for someone to purchase.
So you're saying CYDY had the strength to go $10 with nothing? So with approval next month it's safe to say $10 will be the bottom then $20, $30, $50
There we go! Headed to $4!!
Looking pretty good coming from the 1.2 billion in revenue with the EUA next month.
I think it's a real possibility OWS have been working behind the scenes for a few months now. They could have been involved in the medicare billing codes for Leronlimab.
I think he's asking in what capacity OWS will assist CytoDyn after approval. Will they buy all existing inventory of Vyrologix/Leronlimab and start production on the next batch.
Looking for that 5am PR full enrollment CD12,. I think NP is holding it so he can drop another PR the following morning. Not gonna be a good week for the shorts
Let's tell it as it is.. CYDY is heading back to $4 in anticipation of a PR, multiple PR's with different major catalyst are expected at any moment.
DON'T BLINK
Volume is the key word. Good luck trying to cover when 50,000 new investors are buying in and no one is selling.
Thanks for sharing, so this could very possibly mean label expansion from long haulers approval to treat this??
Why would you wait for the halt from pending approval news and buy at $30.00 when you can buy now and make 1000%.
The only question is which PR is going to drop first, full CD12 enrollment? Long haulers? Philippines approval? I think it will be something unexpected news from Canada? UK? What ever it is DONT BLINK it's coming at any moment.
CYDY will be an easy 10 bagger after approval, and that's just the beginning. This stock has the strength to hit $10 before an approval it's going to run like crazy after. Don't blink
Yes absolutely incredible this stock has the strength to run to $10 without an approval. An OTC that peaked to $10!! I've never seen that. And with approval coming at anytime, could be as early as this week from Philippines $10 will only be the beginning.
So CYDY which is an OTC penny stock is at $3.14 a share. Why is a penny stock (that obviously should only be in the pennies) be at $3.14? It's very very rare for an OTC to brake out into a dollar, let alone $3. Looks like the market approves and is anticipating this stock to run much higher.
I would think future indications for Lero would be calculated in. Even if only a conservative number of say 20% of possible indications are factored in that would have to be near 100 billion.
I'm liking of the idea of CytoDyn becoming a major pharma company with a market cap of 200 billion within 5 years!!
It mainly depends on the trading platform. TD Ameritrade does not allow trading OTC on margin.
It stands at $3.14. It's a penny stock. Why is a penny stock at $3.14?? Show me another penny stock that ran to $10. Show me another penny stock that's at $3.14. The reason this is at $3.14 now is it will be a ten bagger early next year or as soon as next week.